Clinical Trials Logo
  1. Home
  2. Vancomycin
  3. NCT04666948

Precision Dosing of Vancomycin in Critically Ill Children — BENEFICIAL  

Vancomycin Clinical Trial

Official title:
A Multicentric, Randomised Controlled Clinical Trial to Study the Impact of Bedside Model-informed Precision Dosing of Vancomycin in Critically Ill Children

Clinical Trial Summary

The overall objective of this project is to investigate the large-scale utility of MIPD of vancomycin at point-of-care in ICU children. This evaluation includes a comparison with the more standard approach on Clinical and patient-oriented measures.

Clinical Trial Description

Vancomycin is an antibiotic with a narrow therapeutic-toxic margin. This means that the minimum and maximum target blood target levels differ little from each other. Too low concentrations will reduce the effect of the antibiotic; higher concentrations may result in serious side effects, including renal toxicity. Vancomycin dosing tailored to the critically ill child is challenging. Currently, the starting dose of vancomycin is calculated on a milligram per kilogram basis, which is the same for all patients. The dose is then adjusted based on a measured vancomycin blood concentration (if too high or too low). Despite this measurement, quickly achieving target concentrations remains a major challenge. This multicenter, individual randomized study investigates the added value of a user-friendly computer program for calculating the vancomycin dose in critically ill children, compared to the current standard-of-care. Specifically, the investigators will study whether the use of this computer program leads to a shorter time to reach target concentrations, a reduction in the number and severity of side effects on the kidney, a reduction in patient burden, and a reduction in time to cure and duration of hospitalization. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04666948
Study type Interventional
Source University Hospital, Ghent
Contact
Status Active, not recruiting
Phase Phase 4
Start date December 28, 2020
Completion date October 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03221023 - Intrawound Vancomycin Prophylaxis for Neural Stimulator Phase 2/Phase 3
Recruiting NCT03456544 - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Not yet recruiting NCT05964114 - First Time Right of Vancomycin N/A
Completed NCT02951702 - Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Phase 4
Completed NCT05535075 - Model-informed Precision Dosing of Vancomycin in Adults Phase 4
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Recruiting NCT05823116 - Continuous vs. Intermittent Infusion Vancomycin Phase 4
Recruiting NCT02456974 - Antibiotic Dosing in Pediatric Intensive Care
Recruiting NCT05257070 - The Clinical Validation of a Dried Blood Spot Method for Vancomycin and Creatinine
Enrolling by invitation NCT03585426 - Vancomycin in the Target Site Treatment of Intracranial Infection Phase 4
Completed NCT04756895 - Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population N/A
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Completed NCT03806543 - The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level
Recruiting NCT04758442 - Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology N/A
Completed NCT04042233 - Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol Phase 4
Recruiting NCT02667418 - Optimal Treatment for Recurrent Clostridium Difficile Phase 4
Recruiting NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes N/A
Completed NCT03453684 - Pharmacokinetics of Preoperative Vancomycin Phase 4